Immune to Cancer: The CRI Blog
-
FDA approves EPKINLY® for relapsed or refractory follicular lymphoma
June 26, 2024, marked a milestone for patients suffering from follicular lymphoma. The FDA approved Genmab’s epcoritamab-bysp… -
What’s in Your Glass? Weighing the Health Risks of Alcohol Consumption
“Just one for the road.” We’ve all heard or said this at a party. Alcohol is a… -
CRI’s 5th Annual Wear White Luncheon Raises Over $40,000
On Thursday, June 20, 2024, the Cancer Research Institute (CRI) celebrated its fifth annual Wear White Luncheon,… -
Keytruda Receives 40th FDA Approval
This week marked a significant milestone in the fight against cancer. On June 17, the FDA approved… -
#Immune2Cancer Day Ignites Support for CRI
The cornerstone of Cancer Immunotherapy MonthTM is #Immune2Cancer Day, June 14, a day dedicated to showcasing the… -
CRI Associate Board Pours Out Hope at UnWINEd
On Thursday, June 13, 2024, the Cancer Research Institute (CRI) Associate Board hosted an unforgettable evening at… -
New Insights on CAR-T Design: Paving the Way for Broader Cancer Applications
The Cancer Research Institute (CRI) is excited to share the latest study from CRI Lloyd J. Old… -
Women in STEM: Shaping the Future Together
(STEM) stands for science, technology, engineering, and mathematics. STEM fields are at the forefront of driving innovation…. -
How to Support Someone With Cancer: A Guide to Making a Difference
Supporting a loved one with cancer is a journey marked by challenges, learning, and profound moments of…
Join CRI in Shaping the Future of Immunotherapy
Support the pioneering work of CRI in advancing immunotherapy.